C&EN Media Group的动态

Another exciting collaboration with C&EN BrandLab! This article explores the transformative role of small molecule oncology drugs in cancer treatment, highlighting how innovative approaches are overcoming therapeutic challenges and advancing patient care. ??? The piece delves into the unique benefits of small molecules, recent breakthroughs in drug development, and how industry leaders like Lonza are helping to accelerate these innovations. A special thank you to Lonza's expert, Charlie Johnson, for sharing invaluable expertise and insights that brought this piece to life. Don’t miss it—check it out here: https://lnkd.in/emeMq_iC #LonzaSM #Oncology #Innovation #SmallMolecules

We are proud to offer a comprehensive range of models to support oncology research. Our models are meticulously developed to provide reliable and reproducible results, ensuring preclinical studies are both efficient and effective. ?? But that's not all! We understand that every research project is unique. That's why we offer custom model development tailored to your specific needs. Our team of experts is ready to collaborate with you to design models that align perfectly with your goals. Let's push the boundaries of oncology research together. Contact us today to learn more about how we can support your next breakthrough! #PreclinicalServices #InVivoModels #CancerResearch #Oncology

??A recent study using our #ResearchChemicals identified the enzyme DECR2 as a promising therapeutic target in treating preclinical models of castration-resistant #ProstateCancer. Read the full study in the British Journal of Cancer: https://okt.to/BlUTnk ??Our extensive cancer portfolio can help from target identification to drug development and generics manufacturing. Explore now: https://okt.to/m4QyZ1 #oncology #oncologyresearch #ProductCitation

??A recent study using our #ResearchChemicals identified the enzyme DECR2 as a promising therapeutic target in treating preclinical models of castration-resistant #ProstateCancer. Read the full study in the British Journal of Cancer: https://okt.to/GsLeHp ??Our extensive cancer portfolio can help from target identification to drug development and generics manufacturing. Explore now: https://okt.to/dqZJEH #oncology #oncologyresearch #ProductCitation

Join experts, Vladimir Bonevski and Kriti Jindal of IQVIA and Lien Lybaert of myNEO Therapeutics, on our latest webinar. Explore the evolving landscape of precision medicine and biomarker testing and its impact on oncology markets across different tumor types and geographies. Sign up: https://bit.ly/4cQjyjj #Oncology #PrecisionMedicine

The precision of LC-MS/MS is a game-changer in the development of antibody-drug conjugates (ADCs), essential for advancing oncology. By providing a detailed analysis of ADC components, LC-MS/MS ensures that new treatments are effective and safe for patients. Explore how this powerful analytical tool is paving the way for better cancer treatment outcomes. #CancerResearch #LCMS #ADCs #Biotechnology https://hubs.li/Q02GcTHJ0

If you want to understand the development of ADC, this article is worth recommending. Thanks to the author, #Raffaele Colombo. Antibody–drug conjugates (#ADC) represent one of the most rapidly expanding treatment modalities in #oncology, with 11 ADCs approved by the FDA and more than 210 currently being tested in clinical trials. Spanning over 40 years, ADC clinical development has enhanced our understanding of the multifaceted mechanisms of action for this class of therapeutics. #ADC #development #oncology #Drug #clinical #preclinical

Antibody-Drug Conjugates (ADCs) are transforming cancer therapy by pairing precision targeting with potent cytotoxic effects. But developing these complex molecules is no simple task. Join Christoph Lederer, Head of Operations Separation & ELISA at Solvias, as he shares insights into the analytical hurdles of ADC development — from merging expertise in both small molecules and biologics to maintaining linker stability and achieving an optimal drug-to-antibody ratio (DAR). Ready to dive deeper? Access our latest white paper for a comprehensive look at the strategies needed to tackle ADC challenges and bring your innovation to its destination. ?? Download it now: https://lnkd.in/eTiBYqa9 #AntibodyDrugConjugates #ADCs #CancerResearch #Oncology

??A recent study using our #ResearchChemicals identified the enzyme DECR2 as a promising therapeutic target in treating preclinical models of castration-resistant #ProstateCancer. Read the full study in the British Journal of Cancer: https://okt.to/R6k34m ??Our extensive cancer portfolio can help from target identification to drug development and generics manufacturing. Explore now: https://okt.to/ZU94BL #oncology #oncologyresearch #ProductCitation

We’re excited to have Dr. Michael Wick, Ph.D., our Chief Scientific Officer, presenting at Tumor Models London tomorrow at 9:00 AM during the general session. His talk, "Signal vs. Noise: Using Clinically Relevant Preclinical Models to Advance Cancer Therapies," will highlight how precision science relies on high-quality, representative models to produce accurate results in preclinical testing. ? Many PDX suppliers prioritize quantity over quality; XenoSTART offers models representing the clinical status of patients who will be treated on early phase trials.?Our platform eliminates the "black box" nature of many models, addressing key questions like their origin, patient annotation history, and whether they represent a relevant patient population—all while ensuring they perform as advertised. ? Discover how the XenoSTART way is redefining preclinical research to advance cancer therapies: https://lnkd.in/ePKU4DSK ? #TumorModelsLondon #PreclinicalResearch #PDXModels